Endo Peace Biomedical Technology CO., LTD.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
This product technology is an applied platform integrated with endoscopy, representing a novel method for hemostatic treatment. The system is indicated for the treatment of gastrointestinal bleeding, such as gastric ulcers, duodenal ulcers, or abdominal tumors. The system comprises a spraying device and functional powder. The product prototype has completed multiple clinical trials and is currently entering the stages of trial production and regulatory certification procedures. (Same as: Endo Peace Biomedical Technology CO., LTD.)
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2023
Unified Business No.
93749142
Status
Active
Number of Employees
0
Total Paid-in
Capital
29,476,500 (NT$)
Location of Company
Taiwan
, Tainan City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Endo Peace Biomedical Technology CO., LTD. was established in September 2023. It was founded by Professor Hsi-Chang Lin from the Department of Internal Medicine, College of Medicine, National Cheng Kung University, along with his university colleagues. The company focuses on the research, development, and manufacturing of endoscopic medical devices. Its core product, the "Functional Powder Spray System," has obtained a medical device license issued by the Ministry of Health and Welfare (MOHW Medical Device Manufacturing No. 008448). This system can be operated in conjunction with endoscopes to assist physicians in delivering powder under endoscopic visualization. It emphasizes ease of operation, stable airflow, high safety, no power requirement, and compatibility with various powders. The product has now entered the market validation phase and is expected to expand to domestic hospitals, clinics, and international markets. In addition to focusing on product development, the company is actively planning clinical collaborations, regulatory compliance, and international market strategies. The company's long-term goal is to establish a globally competitive endoscopic powder therapy platform, providing safe, stable, and clinically-needed medical solutions. (Also known as: Ching Hsing Biomedical Co., Ltd.)
(The content above was translated by AI.)
(The content above was translated by AI.)
